Organic compounds -- part of the class 532-570 series – Organic compounds – Oxygen containing
Patent
1987-05-18
1989-07-25
Chan, Nicky
Organic compounds -- part of the class 532-570 series
Organic compounds
Oxygen containing
549416, C07C 43215
Patent
active
048515868
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
The novel 1,4-naphthalenediol and 1,4-hydroquinone compounds of the present invention are 5-lipoxygenase and leukotriene inhibitors and as such are useful for treating diseases that result in bronchial constriction such as bronchial asthma, bronchitis, brochiectasis, pneumonia and emphysema. Some of the compounds of this invention also exhibit varying degrees of thromboxane A.sub.2 synthetase inhibiting activity and/or cyclooxygenase inhibiting activity as well. For many of the intended applications, such as asthma, bronchitis, brochiectasis, pneumonia and emphysema, the combination of the three inhibiting effects may be desirable for some of the intended applications.
The leukotrienes are a class of unsaturated fatty acid compounds which are derived from arachidonic acid by the action of lipoxygenase. See, e.g., Samuelsson, Trends in Pharmacological Sciences, 5: 227 (1980); and Samuelsson, et al., Annu. Rev. Biochem. 47: 997-1029 (1978). For a discussion of leukotriene nomenclature, see Samuelsson, et al., Prostaglandins, 19: 645 (1980).
The leukotrienes have been found to be potent constrictors of human bronchi. That is, certain leukotrienes are mediators of the action of slow-reacting substance of anaphylaxis (SRS-A). See, e.g., Dhalen, Nature, 288: 484 (1980). These compounds are therefore important mediators of bronchoconstriction in humans.
The role of leukotrienes as agonists in immediate hypersensitivity and other pathological conditions had led to research into leukotriene antagonists and inhibitors of leukotriene biosynthesis. See, e.g., Corey, et al., Tet. Lett. 21: 4243 (1980).
Leukotrienes, particularly leukotriene C.sub.4 (LTC.sub.4) and leukotriene D.sub.4 (LTD.sub.4) have been shown to be potent mucus secretagogues. Mucus secreted from submucosal glands and surfaces at the epithelial cells combines with water to form part of the respiratory tract secretions. In healthy states mucus secretion in the respiratory tract is about 50 to 150 ml per day in man. The excessive production of mucus, however, is an important feature of many pulmonary diseases. For example, in chronic bronchitis the flow of mucus increases up to fourfold. The lack of the ability of the patient to deal with this hyper-production leads to pathological conditions of the airways such as chronic bronchitis, asthma, and cystic fibrosis where there is a defect in consistency or clearance of the mucus. Therefore it is medically desirable to regulate the hypersecretion of mucus (J. G. Widdicobe, Brit. Med. Bull. 34, 57-31 (1978)). Historically attempts have been made to treat the symptoms without regulation of the root cause. For example, mucolytics, acetylcysteine containing solutions, as well as iodides have been used. Also, antibiotics are used to treat infections in cystic fibrosis because no known drug can regulate the consistency of the mucus in this disease condition. Both LTC.sub.4 and LTD.sub.4 increase the release of mucus from human airways in vitro, Z. Maron, et al., Am. Rev. Respir. Dis. 126, 449-451 (1982); S. J. Coles, et al., Prostaglandins 25, 155-170 (1983), and from canine tracheas in vivo, H. G. Johnson, et al., Int. J. Immunopharmacol. 5, 178 (1983); H. G. Johnson, et al., Prostaglandins 25, 237-243 (1983). Arachidonic acid, metabolic products or arachidonic acid, monohydroxy-eicosatetraenoic acid, and prostaglandins also release mucus from human airways, Z. Maron, et al., J. Clin. Invest. 67, 1695-1702 (1981). LTC.sub.4 was effective in stimulating mucus release in vivo in the cat but not in vitro in cat trachea tissue, A. C. Peatfield, et al., Br. J. Pharmac. 77, 391-393 (1982). J. H. Shelhamer, et al., Chest. 81, 36s (1982) summarizes the nature of evidence available suggesting that lipoxygenase products generated by the airways in vitro might be responsible for the augmented mucus release.
O. Cromwell, et al., The Lancet, July 25, 1981, pp. 164-165, identified LTB.sub.4 and LTD.sub.4 in the sputum of cystic fibrosis patients and speculated, therefore, that inhibitors of the li
REFERENCES:
patent: 4102902 (1978-07-01), Archer et al.
patent: 4388312 (1983-06-01), Terao et al.
patent: 4407757 (1983-10-01), Morimoto et al.
Snyder et al., JACS, 96, 8046 (1974).
M. Shiraishi et al., Synthesis of Quinone Derivatives having Ethylenic and Acetylenic Bonds: Specific Inhibitors of the Formation of Leukotrienes and 5-Hydroxyicosa-6,8,11,14-tetraenoic Acid (5-HETE), J. Chem. soc. Perkin Trans. I, 1591-1599 (1983).
T. Yoshimoto et al., 2,3,5-Trimethyl-6-(12-Hydroxy-5,10-Dodecadiynyl)1,4-Benzoquinone (AA861), A Selective Inhibitor of the 5-Lipoxygenase Reaction and the Biosynthesis of Slow-Reacting Substance of Anaphylaxis, Biochim. Biophys. Acta., 713:470-473 (1982).
Y. Ashida et al., Pharmacological Profile of AA-861, A 5-Lipoxygenase Inhibitor, Prostaglandins 26(No. 6):955-972 (1983).
K. Ohuchi et al., Inhibition by AA861 of Prostaglandin E.sub.2 Production by Activated Peritoneal Macrophages of Rat, Prostaglandins, Leukotrienes and Medicine, 12:175-77 (1983).
M. Shiraishi et al., Studies on the Synthesis of 5-Lipoxygenase Inhibitors, J. Pharmacobiodyn, 7:S-95 (1984), Derwent Abstract 84-44729.
S. Yamamoto et al., Arachidonate 5-lipoxygenase and its new inhibitors, J. Allergy Clin. Immunol., 74:349-352 (1984).
Bundy Gordon L.
Lin Chiu-Hong
Chan Nicky
Cox Martha
The Upjohn Company
LandOfFree
1,4-naphthalenediol and 1,4-hydroquinone derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,4-naphthalenediol and 1,4-hydroquinone derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,4-naphthalenediol and 1,4-hydroquinone derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2359622